Last reviewed · How we verify

Cardioversion of Atrial Fibrillation — Treatment Landscape & Competitive Intelligence

Cardioversion of Atrial Fibrillation (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Cardioversion of Atrial Fibrillation, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Tikosyn DOFETILIDE Pfizer Antiarrhythmic [EPC] Potassium voltage-gated channel subfamily H member 2 1999-01-01
Corvert IBUTILIDE Pfizer Antiarrhythmic Potassium voltage-gated channel subfamily H member 2 1995-01-01
Quinidine Gluconate QUINIDINE SULFATE Eli Lilly Antiarrhythmic Muscarinic acetylcholine receptor M2 1950-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 2 drugs in Cardioversion of Atrial Fibrillation
  2. · 1 drug in Cardioversion of Atrial Fibrillation
  3. Eli Lilly · 1 drug in Cardioversion of Atrial Fibrillation

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Cardioversion of Atrial Fibrillation:

Cite this brief

Drug Landscape (2026). Cardioversion of Atrial Fibrillation — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/cardioversion-of-atrial-fibrillation. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing